CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells

Journal of Immunology

Volumn 192, Issue 9, 2014, Pages 4184-4191

  Stojanovic, Ana ^a   Fiegler, Nathalie ^a   Brunner Weinzierl, Monika ^b   Cerwenka, Adelheid ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL EXPANSION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; LUNG CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; UPREGULATION;

ANIMALS; ANTIGENS, CD28; CELL SEPARATION; CTLA-4 ANTIGEN; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84899515283     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302091     Document Type: Article

References (59)

1. Vidal, S. M., S. I. Khakoo, and C. A. Biron. 2011. Natural killer cell responses during viral infections: Flexibility and conditioning of innate immunity by experience. Curr. Opin. Virol. 1: 497-512
2. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339
3. Long, E. O., H. S. Kim, D. Liu, M. E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu. Rev. Immunol. 31: 227-258
4. Lauwerys, B. R., J. C. Renauld, and F. A. Houssiau. 1999. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 11: 822-830
5. Okamura, H., S. Kashiwamura, H. Tsutsui, T. Yoshimoto, and K. Nakanishi. 1998. Regulation of interferon-gamma production by IL-12 and IL-18. Curr. Opin. Immunol. 10: 259-264
6. Laouar, Y., F. S. Sutterwala, L. Gorelik, and R. A. Flavell. 2005. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 6: 600-607
7. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100: 4120-4125
8. Chen, L., and D. B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13: 227-242
9. Rudd, C. E., A. Taylor, and H. SchneiDer. 2009. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229: 12-26
10. Pentcheva-Hoang, T., E. Corse, and J. P. Allison. 2009. Negative regulators of T-cell activation: Potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev. 229: 67-87
11. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547
12. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorDers with early lethality in mice deficient in Ctla-4. Science 270: 985-988
13. Mandelbrot, D. A., A. J. McAdam, and A. H. Sharpe. 1999. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 189: 435-440
14. Tivol, E. A., S. D. Boyd, S. McKeon, F. Borriello, P. Nickerson, T. B. Strom, and A. H. Sharpe. 1997. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158: 5091-5094
15. Bachmann, M. F., G. Köhler, B. Ecabert, T. W. Mak, and M. Kopf. 1999. Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 163: 1128-1131
16. Corse, E., and J. P. Allison. 2012. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J. Immunol. 189: 1123-1127
17. Wang, C. J., R. Kenefeck, L. Wardzinski, K. Attridge, C. Manzotti, E. M. Schmidt, O. S. Qureshi, D. M. Sansom, and L. S. Walker. 2012. Cutting edge: Cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J. Immunol. 189: 1118-1122
18. Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, et al. 2011. Transendocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603
19. Bour-Jordan, H., J. H. Esensten, M. Martinez-Llordella, C. Penaranda, M. Stumpf, and J. A. Bluestone. 2011. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol. Rev. 241: 180-205
20. Wing, K., T. Yamaguchi, and S. Sakaguchi. 2011. Cell-autonomous and -nonautonomous roles of CTLA-4 in immune regulation. Trends Immunol. 32: 428-433
21. Geldhof, A. B., M. Moser, L. Lespagnard, K. Thielemans, and P. De Baetselier. 1998. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91: 196-206
22. Kelly, J. M., K. Takeda, P. K. Darcy, H. Yagita, and M. J. Smyth. 2002. A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J. Immunol. 168: 4472-4479
23. Nandi, D., J. A. Gross, and J. P. Allison. 1994. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J. Immunol. 152: 3361-3369
24. Hunter, C. A., L. Ellis-Neyer, K. E. Gabriel, M. K. Kennedy, K. H. Grabstein, P. S. Linsley, and J. S. Remington. 1997. The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J. Immunol. 158: 2285-2293
25. Chiossone, L., J. Chaix, N. Fuseri, C. Roth, E. Vivier, and T. Walzer. 2009. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113: 5488-5496
26. Terme, M., E. Ullrich, L. Aymeric, K. Meinhardt, J. D. CouDert, M. Desbois, F. Ghiringhelli, S. Viaud, B. Ryffel, H. Yagita, et al. 2012. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 72: 2757-2767
27. Alegre, M. L., P. J. Noel, B. J. EisfelDer, E. Chuang, M. R. Clark, S. L. Reiner, and C. B. Thompson. 1996. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157: 4762-4770
28. Bhatia, S., M. Edidin, S. C. Almo, and S. G. Nathenson. 2006. B7-1 and B7-2: Similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol. Lett. 104: 70-75
29. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: Cross-talk releVant in innate anti-tumor immune responses in vivo. Nat. Med. 5: 405-411
30. Malek, T. R. 2008. The biology of interleukin-2. Annu. Rev. Immunol. 26: 453-479
31. Arend, W. P., G. Palmer, and C. Gabay. 2008. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223: 20-38
32. Langrish, C. L., B. S. McKenzie, N. J. Wilson, R. de Waal Malefyt, R. A. Kastelein, and D. J. Cua. 2004. IL-12 and IL-23: Master regulators of innate and adaptive immunity. Immunol. Rev. 202: 96-105
33. Brady, J., S. Carotta, R. P. Thong, C. J. Chan, Y. Hayakawa, M. J. Smyth, and S. L. Nutt. 2010. The interactions of multiple cytokines control NK cell maturation. J. Immunol. 185: 6679-6688
34. Yang, L., Y. Pang, and H. L. Moses. 2010. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31: 220-227
35. Ikushima, H., and K. Miyazono. 2010. TGFbeta signalling: A complex web in cancer progression. Nat. Rev. Cancer 10: 415-424
36. Connolly, E. C., J. Freimuth, and R. J. Akhurst. 2012. Complexities of TGF-b targeted cancer therapy. Int. J. Biol. Sci. 8: 964-978
37. Carbone, E., G. Terrazzano, G. Ruggiero, D. Zanzi, A. Ottaiano, C. Manzo, K. Kärre, and S. Zappacosta. 1999. Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol. 29: 4022-4029
38. Piccioli, D., S. Sbrana, E. Melandri, and N. M. Valiante. 2002. Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195: 335-341
39. Moretta, L., G. Ferlazzo, C. Bottino, M. Vitale, D. Pende, M. C. Mingari, and A. Moretta. 2006. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214: 219-228
40. Gao, J. X., X. Liu, J. Wen, M. A. Caligiuri, I. Stroynowski, P. Zheng, and Y. Liu. 2003. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood 102: 4456-4463
41. Chambers, B. J., M. Salcedo, and H. G. Ljunggren. 1996. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5: 311-317
42. Galea-Lauri, J., D. Darling, S. U. Gan, L. Krivochtchapov, M. Kuiper, J. Gäken, B. Souberbielle, and F. Farzaneh. 1999. Expression of a variant of CD28 on a subpopulation of human NK cells: Implications for B7-mediated stimulation of NK cells. J. Immunol. 163: 62-70
43. Goodier, M. R., and M. Londei. 2004. CD28 is not directly involved in the response of human CD3-CD56+ natural killer cells to lipopolysaccharide: A role for T cells. Immunology 111: 384-390
44. Luque, I., H. Reyburn, and J. L. Strominger. 2000. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum. Immunol. 61: 721-728
45. Terrazzano, G., D. Zanzi, C. Palomba, E. Carbone, S. Grimaldi, S. Pisanti, S. Fontana, S. Zappacosta, and G. Ruggiero. 2002. Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferon-gamma production by human natural killer effectors. J. Leukoc. Biol. 72: 305-311
46. Terrazzano, G., S. Pisanti, S. Grimaldi, M. Sica, S. Fontana, E. Carbone, S. Zappacosta, and G. Ruggiero. 2004. Interaction between natural killer and dendritic cells: The role of CD40, CD80 and major histocompatibility complex class i molecules in cytotoxicity induction and interferon-gamma production. Scand. J. Immunol. 59: 356-362
47. Lang, S., N. L. Vujanovic, B. Wollenberg, and T. L. Whiteside. 1998. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur. J. Immunol. 28: 780-786
48. Li, J., Y. Yang, H. Inoue, M. Mori, and T. Akiyoshi. 1996. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: Its regulation by interferon gamma and interleukin-10. Cancer Immunol. Immunother. 43: 213-219
49. Tsukada, N., S. Aoki, S. Maruyama, K. Kishi, M. Takahashi, and Y. Aizawa. 1997. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J. Exp. Clin. Cancer Res. 16: 171-176
50. Whiteway, A., T. Corbett, R. AnDerson, I. Macdonald, and H. G. Prentice. 2003. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br. J. Haematol. 120: 442-451
51. Amakata, Y., Y. Fujiyama, A. Andoh, K. Hodohara, and T. Bamba. 2001. Mechanism of NK cell activation induced by coculture with dendritic cells Derived from peripheral blood monocytes. Clin. Exp. Immunol. 124: 214-222
52. Degli-Esposti, M. A., and M. J. Smyth. 2005. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5: 112-124
53. Draghi, M., A. Pashine, B. Sanjanwala, K. Gendzekhadze, C. Cantoni, D. Cosman, A. Moretta, N. M. Valiante, and P. Parham. 2007. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J. Immunol. 178: 2688-2698
54. Ferlazzo, G., M. L. Tsang, L. Moretta, G. Melioli, R. M. Steinman, and C. Munz. 2002. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195: 343-351
55. Jinushi, M., T. Takehara, T. Kanto, T. Tatsumi, V. Groh, T. Spies, T. Miyagi, T. Suzuki, Y. Sasaki, and N. Hayashi. 2003. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: Impairment in chronic hepatitis C virus infection. J. Immunol. 170: 1249-1256
56. Demaria, S., N. Kawashima, A. M. Yang, M. L. Devitt, J. S. Babb, J. P. Allison, and S. C. Formenti. 2005. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11: 728-734
57. Hurwitz, A. A., B. A. Foster, E. D. Kwon, T. Truong, E. M. Choi, N. M. Greenberg, M. B. Burg, and J. P. Allison. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60: 2444-2448
58. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736
59. Van Elsas, A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366